Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections

Expert Opinion on Drug Delivery

Volumn 4, Issue 6, 2007, Pages 677-688

  Gamazo, Carlos ^a   Prior, Sandra ^a   Lecároz, María Concepción ^a   Vitas, Ana Isabel ^a   Campanero, Miguel Angel ^b   Pérez, Guiomar ^a,b   Gonzalez, David ^a   Blanco Prieto, María Jose ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Drug delivery systems; Liposomes; Microparticles; Nanoparticles; Treatment

Indexed keywords

AMINOGLYCOSIDE; COPOLYMER; GENTAMICIN; LIPOSOME; NANOPARTICLE; PLACEBO; POLYGLACTIN; POLYLACTIC ACID; WATER;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BIODEGRADABILITY; BRUCELLOSIS; CELLULAR DISTRIBUTION; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; INTERNALIZATION; INTRACELLULAR SPACE; MICROENCAPSULATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PARTICLE SIZE; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; SPRAY DRYING;

ANIMALS; BACTERIAL INFECTIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENTAMICINS; HUMANS; INFUSIONS, PARENTERAL; LIPOSOMES; NANOPARTICLES;

EID: 36649035710     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.6.677     Document Type: Review

References (101)

1. ZEMBOWER TR, NOSKIN GA, POSTELNICK MJ, NGUYEN C, PETERSON LR: The utility of aminoglycosides in an era of emerging drug resistance. Int. J. Antimicrob. Agents (1998) 10(2):95-105.
2. YOUNG EJ: An overview of human brucellosis. Clin. Infect. Dis. (1995) 21(2):283-289; quiz 290.
3. MORTENSEN JE, MOORE DG, CLARRIDGE JE, YOUNG EJ: Antimicrobial susceptibility of clinical isolates of Brucella. Diagn. Microbiol. Infect. Dis. (1986) 5(2):163-169.
4. ROLAIN JM, MAURIN M, RAOULT D: Bactericidal effect of antibiotics on Bartonella and Brucella spp.: clinical implications. J. Antimicrob. Chemother. (2000) 46(5):811-814.
5. JONES AT, GUMBLETON M, DUNCAN R: Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv. Drug Deliv. Rev. (2003) 55(11):1353-1357.
6. MAURIN M, RAOULT D: Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob. Agents Chemother. (2001) 45(11):2977-2986.
7. MYRDAL SE, JOHNSON KC, STEYGER PS: Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis. Hear. Res. (2005) 204(1-2):156-169.
8. MOESTRUP SK, CUI S, VORUM H et al.: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. (1995) 96(3):1404-1413.
9. KALATZIS V, NEVO N, CHERQUI S, GASNIER B, ANTIGNAC C: Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum. Mol. Genet. (2004) 13(13):1361-1371.
10. +-coupled electrogenic lysosomal amino acid transporter LYAAT1 localizes to the axon and plasma membrane of hippocampal neurons. J. Neurosci. (2003) 23(4):1265-1275.
11. SANDOVAL RM, MOLITORIS BA: Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am. J. Physiol. Renal Physiol. (2004) 286(4):F617-F624.
12. SERVAIS H, JOSSIN Y, VAN BAMBEKE F, TULKENS PM, MINGEOT-LECLERCQ MP: Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob. Agents Chemother. (2006) 50(4):1213-1221.
13. GRABE M, OSTER G: Regulation of organelle acidity. J. Gen. Physiol. (2001) 117(4):329-344.
14. AMSTERDAM D: Antibiotics in laboratory medicine (1996).
15. DREVETS DA, CANONO BP, LEENEN PJ, CAMPBELL PA: Gentamicin kills intracellular Listeria monocytogenes. Infect. Immun. (1994) 62(6):2222-2228.
16. BAUDOUX P, BLES N, LEMAIRE S et al.: Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J. Antimicrob. Chemother. (2007) 59(2):246-253.
17. MINGEOT-LECLERCQ MP, GLUPCZYNSKI Y, TULKENS PM: Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. (1999) 43(4):727-737.
18. NEW RRC: Liposomes: A Practical Approach. New RRC (Ed.), IRL Press, Oxford (1990):33.
19. GREGORIADIS G: The carrier potential of liposomes in biology and medicine (first of two parts). N. Engl. J. Med. (1976) 295(13):704-710.
20. MORGAN JR, WILLIAMS KE: Preparation and properties of liposome-associated gentamicin. Antimicrob. Agents Chemother. (1980) 17(4):544-548.
21. KARLOWSKY JA, ZHANEL GG: Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin. Infect. Dis. (1992) 15(4):654-667.
22. SCHIFFELERS R, STORM G, BAKKER-WOUDENBERG I: Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. (2001) 48(3):333-344.
23. BAKKER-WOUDENBERG IA, TEN KATE MT, STEARNE-CULLEN LE, WOODLE MC: Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis. (1995) 171(4):938-947.
24. SALEM FD II, DÜZGÜNEŞ N: Liposome-encapsulated antibiotics. Methods Enzymol. (2005) 391:261-291.
25. ELORZA B, ELORZA MA, SAINZ MC, CHANTRES JR: Comparison of particle size and encapsulation parameters of three liposomal preparations. J. Microencapsul. (1993) 10(2):237-248.
26. LUTWYCHE P, CORDEIRO C, WISEMAN DJ et al.: Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. (1998) 42(10):2511-2520.
27. ELORZA B, ELORZA MA, SAINZ MC, CHANTRES JR: Analysis of the particle size distribution and internal volume of liposomal preparations. J. Pharm. Sci. (1993) 82(11):1160-1163.
28. GREGORIADIS G: Overview of liposomes. J. Antimicrob. Chemother. (1991) 28(Suppl. B):39-48.
29. VITAS AI, DIAZ R, GAMAZO C: Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrob. Agents Chemother. (1996) 40(1):146-151.
30. TULKENS PM: Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives. Am. J. Med. (1986) 80(6B):105-114.
31. MINGEOT-LECLERCQ MP, SCHANCK A, RONVEAUX-DUPAL MF et al.: Ultrastructural, physico-chemical and conformational study of the interactions of gentamicin and bis(β-diethylaminoethylether) hexestrol with negatively-charged phospholipid layers. Biochem. Pharmacol. (1989) 38(5):729-741.
32. KUBO M, GARDNER MF, HOSTETLER KY: Binding of propranolol and gentamicin to small unilamellar phospholipid vesicles. Contribution of ionic and hydrophobic forces. Biochem. Pharmacol. (1986) 35(21):3761-3765.
33. HOPE MJ, BALLY MB, MAYER LD, JANOFF AS, CULLIS PR: Generation of multilamellar and unilamellar phospholipid vesicles. Chem. Phys. Lipids (1986) 40:89-107.
34. LICHTENBERG D, MARKELLO T: Structural characteristics of phospholipid multilamellar liposomes. J. Pharm. Sci. (1984) 73:122-125.
35. MINGEOT-LECLERCQ MP, LAURENT G, TULKENS PM: Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. (1988) 37(4):591-599.
36. SCHERPHOF G, VAN LEEUWEN B, WILSCHUT J, DAMEN J: Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposomal membrane. Biochim. Biophys. Acta (1983) 732(3):595-599.
37. SENIOR J, GREGORIADIS G, MITROPOULOS KA: Stability and clearance of small unilamellar liposomes. Studies with normal and lipoprotein-deficient mice. Biochim. Biophys. Acta (1983) 760(1):111-118.
38. TALL AR, SMALL DM: Solubilisation of phospholipid membranes by human plasma high density lipoproteins. Nature (1977) 265(5590):163-164.
39. KRUPP L, CHOBANIAN AV, BRECHER PI: The in vivo transformation of phospholipid vesicles to a particle resembling HDL in the rat. Biochem. Biophys. Res. Commun. (1976) 72(4):1251-1258.
40. KIRBY C, GREGORIADIS G: Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers. Biochem. J. (1981) 199(1):251-254.
41. ABSOLOM DR: Methods in Enzymology. Sabato GD, Everse J (Eds), Academic Press, Toronto (1986):95-180.
42. GUO LS, HAMILTON RL, GOERKE J, WEINSTEIN JN, HAVEL RJ: Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. J. Lipid Res. (1980) 21(8):993-1003.
43. OP DEN KAMP JA, KAUERZ MT, VAN DEENEN LL: Action of pancreatic phospholipase A2 on phosphatidylcholine bilayers in different physical states. Biochim. Biophys. Acta (1975) 406(2):169-177.
44. CORDEIRO C, WISEMAN DJ, LUTWYCHE P et al.: Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model. Antimicrob. Agents Chemother. (2000) 44(3):533-539.
45. GAMAZO C, LECAROZ MC, PRIOR S et al.: Chemical and biological factors in the control of Brucella and brucellosis. Curr. Drug Deliv. (2006) 3(4):359-365.
46. ALLEN TM, CLELAND LG: Serum-induced leakage of liposome contents. Biochim. Biophys. Acta (1980) 597(2):418-426.
47. JULIANO RL: In: Liposomes: from Physical Structure to Therapeutic Applications. Knight CG, Elsevier, North Holland Biomedical Press, NY (1981):391-407.
48. HUTH US, SCHUBERT R, PESCHKA-SUSS R: Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J. Control Rel. (2006) 110(3):490-504.
49. ALLEN TM, AUSTIN GA, CHONN A, LIN L, LEE KC: Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta (1991) 1061(1):56-64.
50. PAPAHADJOPOULOS D, POSTE G, SCHAEFFER BE: Fusion of mammalian cells by unilamellar lipid vesicles: inflluence of lipid surface charge, fluidity and cholesterol. Biochim. Biophys. Acta (1973) 323(1):23-42.
51. DIJKSTRA J, VAN GALEN M, SCHERPHOF G: Influence of liposome charge on the association of liposomes with Kupffer cells in vitro effects of divalent cations and competition with latex particles. Biochim. Biophys. Acta (1985) 813(2):287-297.
52. GABIZON A, PAPAHADJOPOULOS D: The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta (1992) 1103(1):94-100.
53. HSU MJ, JULIANO RL: Interactions of liposomes with the reticuloendothelial system. II. Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim. Biophys. Acta (1982) 720(4):411-419.
54. SENIOR JH, TRIMBLE KR, MASKIEWICZ R: Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta (1991) 1070(1):173-179.
55. HERNANDEZ-CASELLES T, VERA A, CRESPO F, VILLALAIN J, GOMEZ-FERNANDEZ JC: Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am. J. Vet. Res. (1989) 50(9):1486-1488.
56. MAGEE WE, GOFF CW, SCHOKNECHT J, SMITH MD, CHERIAN K: The interaction of cationic liposomes containing entrapped horseradish peroxidase with cells in culture. J. Cell Biol. (1974) 63(2 Part 1):492-504.
57. SCHWENDENER RA, LAGOCKI PA, RAHMAN YE: The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim. Biophys. Acta (1984) 772(1):93-10l.
58. VITAS AI, DIAZ R, GAMAZO C: Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Chemotherapy (1997) 43(3):204-210.
59. MAJUMDAR S, FLASHER D, FRIEND DS et al,: Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages. Antimicrob. Agents Chemother. (1992) 36(12):2808-2815.
60. CYNAMON MH, SWENSON CE, PALMER GS, GINSBERG RS: Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. (1989) 33(8):1179-1183.
61. OROZCO LC, QUINTANA FO, BELTRAN RM et al.: The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle (1986) 67(2):91-97.
62. DIJKSTRA J, VAN GALEN WJ, HULSTAERT CE et al.: Interaction of liposomes with Kupffer cells in vitro. Exp. Cell Res. (1984) 150(1): 161-176.
63. COUVREUR P, PUISIEUX F: Nano- and micro-particles for the delivery of polypeptides and proteins. Av. Drug Deliv. Rev. (1993) 10:141-162.
64. ATHANASIOU KA, NIEDERAUER GG, AGRAWAL CM: Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials (1996) 17(2):93-102.
65. WADA R, HYON S-H, IKADA Y, YOSHIKAWA H, MURANISHI: Lactic acid oligomer microspheres containing an anticancer agent for selective lymphatic delivery. I. In vitro studies. J. Bioact. Compat. Polymer (1988) 3: 126-136.
66. LEELARASAMEE N, HOWARD SA, MALANGA CJ et al.: Kinetics of drug release from polylactic acid-hydrocortisone microcapsules. J. Microencapsul. (1986) 3(3):171-179.
67. KERSTEN GFA, GANDER B: Concepts in Vaccine Development. Kaufmann SHE (Ed.), Walter de Gruyter, New York (1996).
68. PAVANETTO F, GENTA I, GIUNCHEDI P, CONTI B: Evaluation of spray drying as a method for polylactide and polylactide-co-glycolide microsphere preparation. J. Microencapsul. (1993) 10(4):487-497.
69. LEWIS DH: Biodegradable Polymers as Drug Delivery Systems. Chasin M (Ed.), Langer, New York (1990):1-41.
70. THOMASIN C, CORRADIN G, MEN Y, MERKLE HP, GANDER B: Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/ poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control Rel. (1996) 41:131-145.
71. ATUAH KN, WALTER E, MERKLE HP, ALPAR HO: Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: a comparison of solvent evaporation and spray-drying methods. J. Microencapsul. (2003) 20(3):387-399.
72. PRIOR S, GAMAZO C, IRACHE JM, MERKLE HP, GANDER B: Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. Int. Pharm. (2000) 196(1):115-125.
73. GANDER B, JOHANSEN P, NAM-TRÂN H, MERKLE HP: Thermodynamic approach to protein microencapsulation into poly(D,L-lactide) by spray drying. Int. J. Pharm. (1996) 129:51-61.
74. NAGATA S, TAKESHIMA K, HIRANO K, TAKAGISHI Y: Pharmaceutical dosage form design of copoly(lactic/glycolic acid) microspheres. Mechanism of in vitro release of gentamicin. Yakugaku Zasshi (1994) 114(12): 1005-1014.
75. BRADFIELD WBJ: Microspheres and Drug Therapy. Davis SS, Illum L, McVie JG, Tomlinson E (Eds), Elsevier Science, Amsterdam (1984):25.
76. RUDT S, MÜLLER RH: In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration. J. Control. Rel. (1992) 22:263-271.
77. MULLER RH, RUHL D, LUCK M, PAULKE BR: Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm. Res. (1997) 14(1):18-24.
78. TABATA Y, IKADA Y: Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials (1988) 9(4):356-362.
79. TABATA Y, IKADA Y: High Perforermance Biomaterials. Szycher M (Ed.), Technomic Publishing, Lancaster PA and Basel, Switzerland (1991):621-646.
80. O'RIEN CN, GUIDRY AJ: Formulation of poly(D,L-lactide-co-glycolide) microspheres and their ingestion by bovine leukocytes. J. Dairy Sci. (1996) 79(11):1954-1959.
81. EVORA C, SORIANO I, ROGERS RA et al.: Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control Rel. (1998) 51(2-3):143-152.
82. PRIOR S, GANDER B, BLARER N et al.: In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. (2002) 15(2):197-207.
83. ILLUM L, JACOBSEN LO, MULLER RH, MAK E, DAVIS SS: Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials (1987) 8(2):113-117.
84. MURILLO M, GAMAZO C, GONI M, IRACHE J, BLANCO-PRIETO M: Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis. Int. J. Pharm. (2002) 242(1-2):341-344.
85. ARTURSSON P, ARRO E, EDMAN P, ERICSSON JL, SJOHOLM I: Biodegradable microspheres. V. Stimulation of macrophages with microparticles made of various polysaccharides. J. Pharm. Sci. (1987) 76(2):127-133.
86. SILVERSTEIN SC, STEINMAN RM, COHN ZA: Endocytosis. Annu. Rev. Biochem. (1977) 46:669-722.
87. NG KY, STRINGER KA, COHEN Z et al.: Alveolar macrophage cell line is not activated by exposure to polymeric microspheres. Int. J. Pharm. (1998) 170:41-49.
88. PRIOR S, GANDER B, LECAROZ C, IRACHE JM, GAMAZO C: Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J. Antimicrob. Chemother. (2004) 53(6):981-988.
89. RUDT S, MÜLLER RH: In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. II. Effect of surface modification by coating of particles with poloxamer on the phagocytic uptake. J. Control. Rel. (1993) 25:51-59.
90. WATROUS-PELTIER N, UHL J, STEEL V, BROPHY L, MERISKO-LIVERSIDGE E: Direct suppression of phagocytosis by amphipathic polymeric surfactants. Pharm. Res. (1992) 9(9):1177-1183.
91. MULLER RH: Colloidal Carriers for Controlled Drug Delivery and Targeting. Müller RH (Ed.), CRC Press, Boston (1991):19-41.
92. SCHAFER V, VON BRIESEN H, ANDREESEN R et al.: Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. (1992) 9(4):541-546.
93. BATRAKOVA E, LEE S, LI S et al.: Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. (1999) 16(9):1373-1379.
94. MILLER DW, BATRAKOVA EV, KABANOV AV: Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. (1999) 16:396-401.
95. ESPUELAS S, LEGRAND P, LOISEAU PM et al.: In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob. Agents Chemother. (2000) 44(8):2190-2192.
96. HUNTER RL, JAGANNATH C, TINKLEY A, BEHLING CA, NOLTE F: Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrob. Agents Chemother. (1995) 39(2):435-439.
97. NEWMAN MJ, ACTOR JK, BALUSUBRAMANIAN M, JAGANNATH C: Use of nonionic block copolymers in vaccines and therapeutics. Crit. Rev. Ther. Drug Carrier Syst. (1998) 15(2):89-142.
98. PRIOR S, GANDER B, IRACHE JM, GAMAZO C: Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J. Antimicrob. Chemother. (2005) 55(6):1032-1036.
99. BLANCO-PRIETO M, LECAROZ C, RENEDO M, KUNKOVA J, GAMAZO C: In vitro evaluation of gentamicin released from microparticles. Int. J. Pharm. (2002) 242(1-2):203-206.
100. LECAROZ C, GAMAZO C, BLANCO-PRIETO MJ: Nanocarriers with gentamicin to treat intracellular pathogens. J. Nanosci. Nanotechnol. (2006) 6(9-10):3296-3302.
101. LECAROZ MC, BLANCO-PRIETO MJ, CAMPANERO MA, SALMAN H, GAMAZO C: Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother. (2007) 51 (4):1185-1190.